Leukemia Research
Volume 29, Issue 7 , Pages 785-791 , July 2005

Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells

  • Philipp Saiko

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • Center of Excellence in Clinical and Experimental Oncology (CLEXO) of the Medical University of Vienna, Austria
    • ,
  • Zsuzsanna Horvath

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • Center of Excellence in Clinical and Experimental Oncology (CLEXO) of the Medical University of Vienna, Austria
    • ,
  • Christoph Illmer

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Sibylle Madlener

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Wolfgang Bauer

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Thomas Hoechtl

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Natascha Erlach

      Affiliations

    • Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
    • ,
  • Michael Grusch

      Affiliations

    • Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
    • ,
  • Georg Krupitza

      Affiliations

    • Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Robert M. Mader

      Affiliations

    • Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Walter Jaeger

      Affiliations

    • Department of Pharmaceutical Chemistry, Faculty of Natural Sciences and Mathematics, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria
    • ,
  • Herbert Schott

      Affiliations

    • Department of Organic Chemistry, Faculty of Chemistry and Pharmacy, University of Tuebingen, Auf der Morgenstelle 18, 72076 Tuebingen, Germany
    • ,
  • Ram P. Agarwal

      Affiliations

    • Department of Medicine, Division of Hematology/Oncology, University of Miami, 1600 N.W. 10th Avenue, Miami, FL 33136, USA
    • ,
  • Monika Fritzer-Szekeres

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • Thomas Szekeres

      Affiliations

    • Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 1 40400x5365; fax: +43 1 320 33 17.

Received 6 September 2004 ,Accepted 17 December 2004.

References 

  1. Kinsella AR, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer. 1997;75:935–945
  2. Fischel JL, Formento P, Etienne MC, Spector T, Renee N, Milano G. Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Pharmacol. 1997;53:1703–1709
  3. Momparler RL. A model for the chemotherapy of acute leukemia with 1-β-d-arabinofuranosylcytosine. Cancer Res. 1967;34:1775–1787
  4. Early A, Preisler HD, Slocum H, Rustum YM. A pilot study of high dose 1-β-arabinofuranosylcytosine for acute leukemia and refractory lymphoma. Cancer Res. 1982;42:1587–1594
  5. Cozzarelli NR. The mechanism of action of inhibitors of DNA synthesis. Annu Rev Biochem. 1977;46:641–668
  6. Cattaneo-Pangrazzi RM, Schott H, Wunderli-Allenspach H, Derighetti M, Schwendener RA. Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells. Biochem Pharmacol. 2000;60:1887–1896
  7. Cattaneo-Pangrazzi RM, Schott H, Schwendener RA. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate. 2000;45:8–18
  8. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288–2295
  9. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048
  10. Agarwal RP, Han T, Fernandez M. Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol. 2001;61:39–47
  11. Fernandez M, Han T, Yo P, Wang W, Agarwal RP. Comparison of arabinosylcytosine and dideoxycytidine induced drug resistance in H9 cells. Proc Am Assoc Cancer Res. 1999;40:676
  12. Van Laar JAM , Rustum JM, Ackland SP, Van Groeningen CJ, Peters GJ. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer. 1997;34:296–306
  13. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–395
  14. Langenbach RJ, Danenberg PV, Heidelberg C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochim Biophys Acta. 1977;473:73–92
  15. Inaba M, Naoe Y, Mitsuhasi J. Mechanism for 5-fluorouracil resistance in human colon cancer DLD-1 cells. Biol Pharm Bull. 1998;21:569–573
  16. Furth JJ, Cohen SS. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res. 1968;28:2061–2067
  17. Kufe D, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 1980;255:8997–9000
  18. Aas T, Borresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814
  19. Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res. 1998;241:96–101
  20. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet. 1993;341:1251–1254
  21. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78:539–542
  22. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121–139
  23. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990;2:275–280
  24. Sommer H, Santi DV. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun. 1974;57:689–695
  25. Cheng YC, Nakayama K. Effects of 5-fluoro-2′-deoxyuridine on DNA metabolism in HeLa cells. Mol Pharmacol. 1983;23:171–174
  26. Fram RJ, Kufe DW. Effect of 1-β-D-arabinofuranosylcytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts. Biochem Pharmacol. 1985;34:2557–2560
  27. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol. 2004;67:503–511

PII: S0145-2126(05)00031-7

doi: 10.1016/j.leukres.2004.12.015

Leukemia Research
Volume 29, Issue 7 , Pages 785-791 , July 2005

Article Tools

* Image Usage & Resolution